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SUMMARY 
Strangles, one of the most common infectious diseases in equids worldwide, is caused by 
Streptococcus equi ssp. equi, and is characterized by clinical signs like fever, nasal- and ocular 
discharge, lymphadenopathy, inappetence and depression. Several complications, like bastard 
strangle, immunomediated reactions and chronic carriage, are known. Outbreaks with S. equi 
can be extensive and proceed for longer periods. Treatment of horses with strangles is debated. 
It is argued that early treatment with antibiotics affect the development of antibodies but there 
is no evidence for this. The aim with this project is to look closer into how treatment with 
antibiotics affect immunity in horses with strangles. 
For the prospective project, 41 naturally strangles infected horses on a Swedish Icelandic horse 
farm were classified into 3 groups. Group 1 included horses treated with antibiotics (penicillin) 
within 16 days after the first horse started showing symptoms (fever), group 2 included horses 
treated between 16 days and 22 days after the first horse started showing symptoms and group 
3 included horses not treated with antibiotics during the acute period. Diagnostics were made 
by qPCR and culture and iELISA serology samples were taken at 7 occasions as a measure of 
the antibody response. Horses with iELISA od units ≥ 0.5 were classified as seropositive. The 
proportion seropositive horses was recorded for each group and the results were compared with 
Fisher’s exact test.  
All horses were classified as seropositive against antigen A on one or more occasions whereas 
for antigen C 3 horses were negative through all sampling occasions. Significant differences 
between group 1 and 2 (higher percentage seropositive horses in group 2 than 1) were seen in 
August 2015 (five months post first clinical sign) for both antigen A and C (P=0,0152) and in 
March 2016 (12 months post first clinical sign) for antigen A (P=0,0152). Between group 1 and 
3, significant differences (higher percentage seropositive horses in group 3 than 1) were only 
observed for antigen A in August 2015 (P=0,0305) and in March 2016 (P=0,0063). No 
significant differences were observed during the first and second sampling occasions (about 4 
and 6 weeks after the beginning of the outbreak) when most horses were positive.  
These results provide support to the hypothesis that antibiotic treatment affects the development 
of immunity. However, many factors should be taken into consideration when interpreting the 
results, including individual variations in immune status between the horses, and that horses 
were continuously immunostimulated during the sampling period. Immunology is a complex 
subject and much is unknown regarding immunology and strangles; in particular whether serum 
antibodies fully reflect the level of immunity to strangles infections. Restrictive use of 
antibiotics is always important but for more evidence based recommendations regarding the 
antibiotic use to horses with strangles, more research is needed. 
  
SAMMANFATTNING 
Kvarka, en av de vanligaste infektionssjukdomarna hos hästdjur världen över, orsakas av 
bakterien Streptococcus equi ssp. equi, och kännetecknas av sjukdomstecken som feber, näs- 
och ögonflöde, lymfadenopati, inappetens och depression. Flera komplikationer, som kastad 
kvarka, immunmedierade reaktioner och kroniskt bärarskap, är kända. Utbrott med S. equi kan 
vara omfattande och fortgå under längre perioder. Antibiotikabehandling vid kvarka är 
omdiskuterat. Det hävdas att tidig behandling med antibiotika påverkar utvecklingen av 
antikroppar men inga bevis finns i litteraturen. Syftet med detta projekt är att se närmare på hur 
behandling med antibiotika påverkar immuniteten hos hästar med kvarka. 
I den prospektiva studien delades 41 naturligt kvarkainfekterade hästar, från en svensk 
islandshästgård, in i 3 grupper. Grupp 1 innefattade de hästar som behandlats med antibiotika 
(penicillin) inom 16 dagar efter det att den första hästen började visa symtom (feber), grupp 2 
de hästar som behandlades mellan 16 dagar och 22 dagar efter att den första hästen började visa 
symtom och grupp 3 de hästar som inte behandlats med antibiotika under den tidiga fasen av 
utbrottet. Diagnostiska metoder som användes var qPCR-analys och odling av nässköljprover. 
Serologiprover analyserades med iELISA vid 7 tillfällen och resultatet användes som ett mått 
på antikroppssvaret. Hästar med iELISA od värden ≥ 0.5 klassades som seropositiva. Andelen 
seropositiva hästar registrerades för varje grupp och resultatet jämfördes med Fishers exakta 
test.  
Alla hästar var positiva för antigen A vid ett eller flera tillfällen och endast 3 hästar var negativa 
för antigen C under alla provtagningstillfällena. Signifikanta skillnader mellan grupp 1 och 2 
(högre andel positiva hästar i grupp 2 än grupp1) sågs i augusti 2015 (fem månader efter första 
kliniska tecknet) för både antigen A och C (P=0,0152) och i mars 2016 (12 månader efter första 
kliniska tecknet) för enbart antigen A (P=0,0152). Mellan grupp 1 och 3 observerades 
signifikanta skillnader (högre andel positiva hästar i grupp 3 än grupp 1) endast för antigen A i 
augusti 2015 (P = 0,0305) och i mars 2016 (P = 0,0063). Inga signifikanta skillnader sågs under 
de två första provtagningstillfällena (ca 4 och 6 veckor efter utbrottets början) då flest hästar 
var seropositiva.  
Resultatet ger visst stöd till hypotesen om att antibiotikabehandling påverkar utvecklingen av 
immuniteten. Hänsyn bör dock tas till flera faktorer vid tolkning av resultatet. Variationer i 
immunstatus mellan olika hästar, studiedesignen och specifika händelser under utbrottet kan ha 
spelat roll. Hästarna var kontinuerligt stimulerade med antigen under provtagnings-perioden. 
Immunologi är ett komplext ämne och mycket är okänt när det gäller immunologi och kvarka; 
speciellt beträffande om antikroppar i serum helt reflekterar graden av immunitet vid 
kvarkainfektion. Restriktiv användning av antibiotika är alltid viktigt, men för mer 
evidensbaserade rekommendationer om antibiotikabehandling vid kvarka, behövs mer 
forskning. 
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INTRODUCTION 
Strangles is one of the most common infectious diseases in equids worldwide. The bacteria 
causing strangles, Streptococcus equi ssp. equi (hereafter S. equi), is highly contagious and can 
cause severe symptoms especially in younger horses (Reed, Bayly & Sellon, 2010). In Sweden, 
strangles were on average diagnosed in 53 stables per year between 2005 and 2014 (SVA, 
2017b). Outbreaks can be extensive and proceed for longer periods. It is difficult to limit the 
spread of strangles and as yet there is no uniformly applicable treatment regime for affected 
horses or entire stables.  
How to best treat horses with strangles is debated. There are some indications that early 
antibiotic treatment inhibits the immunological response and that treatment of horses with 
strangles only prolongs the course of the disease (Piché, 1984). Another hypothesis is that 
antibiotic treatment of horses with abscesses can increase the risk of bastard strangles 
(Harrington, Sutcliffe & Chanter, 2002; Sweeney et al., 2005; Reed, Bayly & Sellon, 2010; 
SVS, 2013; Waller, 2014). However, most of these hypotheses are based on limited research or 
lacking hypothesis based studies. More research, using improved diagnostic methods, is needed 
to examine what evidence there is for such statements and thereby assist in the establishment 
of scientifically based treatment guidelines. 
The aim of this study is to examine whether there is any association between treatment with 
antibiotics in horses in an early stage of strangles and the development of seropositivity to S.  
equi after treatment. 
LITERATURE REVIEW 
Etiology 
Strangles is caused by the gram positive beta hemolytic bacteria Streptococcus equi ssp. equi 
(hereafter termed S. equi). The DNA of S. equi is almost identical to the DNA of Streptococcus 
equi ssp. zooepidemicus (hereafter termed S. zooepidemicus) and is suggested to have evolved 
from an archetype of the latter. However, the bacteria differ greatly in biology and 
pathogenicity. S. zooepidemicus generally does not cause respiratory disease in equids and is 
sometimes found in the upper respiratory tract of healthy horses. In certain cases, however S. 
zooepidemicus can cause strangles-like disease in horses (Lindahl, 2013). Immunity against S. 
zooepidemicus does not protect against S. equi (Timoney, 2004; Waller & Jolley, 2007; Reed, 
Bayly & Sellon, 2010; Lindahl et al., 2013; Waller, 2014).  
Pathogenesis 
The incubation time for S. equi is 3 to 14 days (Sweeney et al., 2005). The bacteria enter the 
horse via the mouth or nose and attaches to naso- and oropharyngeal tonsil cells as well as to 
the epithelium of pharynx. Within hours it reaches deeper tonsil tissues and lymph nodes 
(Timoney & Kumar, 2008). Chemotactic complement factors attract a large number of 
granulocytes. Examples of antiphagocytic virulence factors, that seem to inhibit granulocytes 
from phagocytosis of the bacteria, are the hyaluronic acid capsule, the SeM-protein and a 
leukocidal toxin (acts toxic to leukocytes) released by the organism. The SeM-protein is an 
immunogenic cell wall protein that binds to fibrinogen and IgG. Fibrinogen binding inhibits 
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deposition of the complement factor C3b on the bacterial surface and phagocytosis by 
neutrophils. A loss of the SeM expression lead to loss of full virulence of the bacteria. The 
antiphagocytic virulence factors lead to an accumulation of bacteria and inflammatory cells. 
Abscesses are formed in the lymph nodes and drainage of these appears to be necessary for 
natural disposal of the organism (Harrington, Sutcliffe & Chanter, 2002; Timoney, 2004; 
Waller & Jolley, 2007).  
Infection sometimes spreads from upper airways and associated lymph nodes. This condition 
has several names like malignant strangles, bastard strangles and metastatic abscessation (Todd, 
1910; Boyle, 2017). Spreading may occur hematogically or via lymph vessels. Bacteria form 
metastasis abscesses in organs of thorax and the abdomen (Timoney 2004; Boyle, 2016) and 
there are also cases when abscesses have been found in the brain (Ford & Lokai, 1980; 
Henderson, 2011).  
Pneumonia can occur secondary to rupturing abscesses in horses with bastard strangles but can 
also develop due to aspiration of S. equi-containing discharge (Boyle, 2016). 
Another complication to strangles, associated with an aseptic necrotizing vasculitis, is called 
purpura haemorrhagica. It is hypothesized to be cause be caused by a type 3 hypersensitivity 
reaction following infection or vaccination. Galan and Timoney (1985b) found that there were 
immune complexes in sera of four horses with signs of purpura haemorrhagica and showed that 
these horses had significantly higher levels of IgA-antibodies than horses without signs of 
purpura haemorrhagica (Galan & Timoney, 1985b; Boyle, 2016). Purpura haemorrhagiga 
appears to be more common in anemic horses (Duffee et al., 2015). 
Myopathies (muscle infarctions and rhabdomyolysis) are other not commonly diagnosed 
complications to strangles. Muscle infarctions are assumed to be secondary to immune 
mediated vasculitis in horses with purpura haemorrhagica while rhabdomyolysis is thought to 
be caused by an immunological cross-reaction between the SeM-protein and myosin (Boyle, 
2017). 
Rupturing of retropharyngeal lymph nodes into the guttural pouches can cause empyema and 
in some cases persisting/chronic infection. Remaining pus in the guttural pouches may dry and 
hardens into so called chondroids (Mallicote, 2015; Boyle, 2016). Why only certain horses 
become chronical carriers is not known but previous exposure, disease severity, immunological 
factors and virulence of the bacteria may play a role (Newton et al., 1997). There is some 
evidence that mutations leading to loss of virulence is more common in S. equi isolates from 
persistent carriers (Chanter et al., 2000; Harris et al., 2015). 
Clinical signs 
Early clinical signs in of strangles are fever and nasal- and ocular discharge. As the disease 
progresses some horses develop lymphadenopathy/lymph node abscesses, cough, depression 
and inappetence. Most commonly abscesses are found in the mandibular and retropharyngeal 
lymph nodes. Narrowing of the pharynx due to enlargement of the retropharyngeal lymph nodes 
can lead to clinical signs like dyspnea, dysphagia and neck extension. External swelling is not 
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always present. The enlarged lymph nodes eventually rupture spontaneously (Evers, 1968; 
Duffee et al., 2015; Boyle, 2017). 
In cases of bastard strangles, clinical signs like colic and dyspnea can be observed. This is 
depending on which organ that is involved. Abscesses in the abdomen often lead to peritonitis. 
Respiratory signs can also be observed in cases of pneumonia caused by aspiration (Boyle, 
2017).  
Horses with purpura haemorrhagica develop clinical signs like edema of the head, trunk and 
distal limbs and petechiations and ecchymoses of mucous membranes. In some cases, the 
antigen-antibody complexes affect other sites and cause symptoms from the gastrointestinal 
tract, muscles, lungs and kidneys (Boyle, 2017).  
Epidemiology 
Strangles is a highly contagious disease with a morbidity up to 100% and a mortality up to 10% 
in naïve populations (Sweeney et al., 2005). However, different definitions of rate measure and 
diagnostic methods with different sensitivity are used in different reports, making it difficult to 
compare different outbreaks (Newton et al., 2000). As a worst case scenario, Ford and Lokai 
(1980) present an outbreak with a morbidity of 100% and a mortality as high as 10%. However, 
management factors likely influenced this mortality level. During this outbreak, weanlings 
arrived at a farm that earlier had problems with strangles. Many of the new yearlings were sick 
at arrival and were mixed with healthy weanlings. Nonetheless, even in a more well managed 
outbreak Piché (1984) reports of a case specific mortality of 3,6% (Piché, 1984). Other reported 
morbidity rates are 84% (Dalgleish et al., 1993) and 53% (Tscheschlok et al., 2017), both based 
on clinical scoring.  
Younger horses between one and five years of age are generally more sensitive and do often 
show more severe clinical signs (Piché, 1984; Sweeney et al., 2005; Reed, Bayly & Sellon, 
2010; Neamat-Allah & El Damaty, 2016). Foals up to three months of age, with immune mares, 
appear to be resistant to early strangles but can develop disease after weaning. Maternal 
antibodies initially reach the foals circulation by passive transfer after colostral ingestion. Later, 
during the first months of the foal’s life, passively ingested immunoglobulins seem to reach the 
nasal mucosa during milk ingestion (Galan & Timoney, 1985a). According to current concepts 
75% of horses surviving the disease become immune for more than five years (Todd, 1910) but 
25 % are susceptible again after only months of time (Timoney, 2004). 
Strangles seems to be more likely to be diagnosed in the spring than in the summer (Duffee et 
al., 2015).  
Transmission 
The bacterium is transmitted directly via nasal discharge or via abscess secrete from infected 
horses. Indirect transmission occurs through contact with contaminated fomites, environment 
and people. According to the ACVIM Consensus Statement, nasal shedding of S. equi normally 
begin 24 to 48 hours after the onset of fever and persists for 2 to 3 weeks in most animals, 
(Sweeney et al., 2005) but not all S. equi infected horses seem to acquire fever. Tscheschlok et 
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al. (2017) reports that 12 of 14 culture positive horses did not have fever at the time of sampling 
and 6 of these did not acquire clinical strangles throughout the outbreak (Tscheschlok et al., 
2017). This is in line with a study were only 78 of 108 strangles infected horses had pyrexia 
(Duffee et al., 2015).  
Some infected horses become chronic/persistent carriers of S. equi. These horses harbor S. equi, 
most commonly in the guttural pouches, for a long time without showing clinical signs. One 
study by Newton et al. (1997), showed that the organism could be detected in guttural pouch 
content, of subclinically infected horses, for at least 39 months. Nasal swab samples from horses 
in the study were intermittently negative (Newton et al., 1997). There is some evidence that 
these chronically infected horses present a risk of spreading strangles but exactly how extensive 
this risk is, is not known (Todd, 1910; Newton et al., 1997; Waller, 2014). Newton et al. (2000) 
analysed nasal lavage samples from horses from three outbreaks that had recovered from 
strangles with PCR or culture, and found the incidence of chronic carriage to be between 9 and 
44% (Newton et al., 2000). New knowledge about diagnostics may make it easier to diagnose 
chronic carriers in the future (Newton et al., 1997; Lindahl et al., 2013). 
Survival in the environment 
There is limited information about the survival of S. equi in the environment and how this 
affects the spreading of the disease. Weese et al. (2009) conclude that survival of the bacteria 
outdoors in late summer conditions is short, in general under three days. In their study, rain, 
surface type or temperature did not affect the survival of the bacteria. Sun light on the other 
hand seemed to decrease the survival time (Weese et al., 2009). Jorm (1992) showed that S. 
equi could survive indoors for 63 days on wood at 2°C (relative humidity at 32 %) and 48 
days on glass or wood at 20°C (relative humidity at 49 %). However, there are many factors, 
not taken into consideration in mentioned studies (Jorm, 1992; Weese et al., 2009) that 
potentially could affect the survival time. 
Diagnostics 
Research about the S. equi genome, has made it possible to develop more sensitive and specific 
tests that makes it easier to diagnose horses with strangles. Commonly used diagnostic methods 
are PCR, bacterial culture and antibody ELISA. Currently, much focus is put on finding 
diagnostic method for identification of chronic carriers (Waller, 2014).  
PCR 
There are PCR-methods for detection of S. equi and for S. zooepidemicus. Real-
time/quantitative PCR (qPCR) is shown to be a more sensitive method to detect S. equi than 
culturing (Båverud, Johansson & Aspan, 2007; Webb et al., 2012; Lindahl et al., 2013). Webb 
et al. (2012) showed that a triple qPCR method (targeting the genes eqbE and SEQ2190) had a 
sensitivity and specificity of 93,9% respective 96,9% (information about clinical stage of 
sampled horses and sample methods were not reported) and Lindahl et al. (2013) demonstrated 
that a nasal lavage samples analysed with a qPCR (targeting the genes sodA and seeI) could 
detect S. equi in over 90% of horses with clinical signs of strangles. However, Tscheschlok et 
al. (2017) reports of an outbreak where only 20 of 34 horses (59%) with clinical strangles had 
qPCR positive nasal swab samples (Tscheschlok et al., 2017). Nasal lavage samples yielded 
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5% more positive results than nasal swab samples in a study with 57 horses (Lindahl et al., 
2013). Nasal samples are reported to be negative up to 24 to 48 hours after the first fever 
(Sweeney et al., 2005). Samples taken directly from abscesses and samples from guttural 
pouches can also be analysed (Lindahl et al., 2013).    
Bacterial culture 
Traditional bacterial culture is, compared to PCR-analysis, considerably less sensitive but can 
detect other bacteria than S. equi and S. zooepidemicus (Sweeney et al., 2005; Lindahl et al., 
2013). Such bacteria can be Actinobacillus spp., Bordetella bronchiseptica and Rhodococcus 
equi (SVA, 2017b). According to Webb et al. (2012) the sensitivity was only 60,3% for 
culturing. Specificity was however as high as 100% (Webb et al., 2012). Culturing is more time 
consuming than PCR. Sample types used for culture are the same as for PCR-analysis (SVA, 
2017a; Waller, 2014).  
Serology 
Serological analyses for detection of S. equi antibodies is used for diagnostics and for disease 
surveillance. One serology method used today is the enzyme-linked immunosorbent assay 
(ELISA). Animal Health Trust (AHT) has developed a combined iELISA-test that examines 
two surface antigens (antigen A and antigen C) which both are unique for S. equi (Knowles, 
2011). Antigen A consists of recombinant N-terminal protein fragments of the SEQ2190 
sequence and antigen C is a part of the SeM protein (Robinson et al., 2013). Robinson at al. 
(2013) found that the sensitivity and specificity for this test is 93,3% respective 99,3%. Another 
ELISA-method from ID vet is solely based on the SeM-antigen and has a sensitivity of 89,9% 
and a specificity of 77,0% (Robinson et al., 2013). Negative pair samples analysed with the 
combined iELISA, taken with an interval of 10-14 days, should allow exclusion of past and 
recent infection (Knowles, 2011; SVA, 2017). 
Hygiene measures 
Hygiene measures are important to reduce the spread of disease and to avoid reinfection. 
Persons handling infected horses should use protecting clothing and dedicated equipment 
should be used to infected horses. It is preferable if different people handle infected and 
susceptible horses but in cases when this is not possible, susceptible horses should be handled 
before infected ones. There are different recommendations regarding how long horses, in 
stables with demonstrated strangles, should be isolated. According to Swedish trotting (2017), 
horses shall be isolated at least until all horses have been free from clinical signs for 20 days 
(Swedish trotting, 2017). SVA (2017b) recommend an isolation time for 4 to 6 weeks (SVA, 
2017b).  
During an outbreak, cleaning of the environment is important to reduce the amount of 
environmental contamination. This should be followed by more extensive cleaning after the 
outbreak. Removing of all organic material should be done before application of suitable 
disinfection. Repeated rounds of disinfection are preferable. Resting of pastures from animals 
for about 4 weeks is also recommended (Sweeney et al., 2005).  
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Prevention 
Isolation of new horses, before contact with a new population, reduce the risk of spreading 
strangles. Sweeney et al. (2005) recommend isolation for three weeks before introduction to 
other horses. It is also preferable if new horses are screened for S. equi by repeated 
nasopharyngeal swabs or lavages or by samples taken from the guttural pouches. During the 
isolation time, hygiene is important to decrease the risk for indirect contamination. Daily 
control of rectal temperatures, nasal discharge and cough in newly arrived horses can make it 
possible to isolate sick horses in an early stage of disease before they start to shed the disease 
(Sweeney et al., 2005; Waller, 2014). 
Vaccines 
Researchers have for a long time tried to develop an effective vaccine against strangles. It is a 
big challenge to produce an effective vaccine without adverse effects. Examples of adverse 
effects associated with earlier and present vaccines are nasal discharge, lymphadenopathy, 
submandibular abscesses, purpura haemorrhagica and severe injection site reactions (Waller, 
2014).  
In Europe, Equilis StrepE (MSD Animal Health) is currently the only available vaccine against 
S. equi (Waller, 2014). This vaccine is however not licensed in Sweden (SVA, 2017b). It is a 
live attenuated vaccine from the TW928 strain on which a deletion of the aroAgene has been 
done. Intramuscular injection gave 100% immunity in one study but was associated with severe 
injection reactions. Pinnacle ® i.m. (Zoetis US) is an intranasal vaccine used in USA. It is live 
attenuated, acapsular and has been treated with nitroguanidine causing chemical mutagenesis. 
Because of earlier mentioned adverse effects it is not licensed in Europe. There are also different 
cell free extract vaccines (Equivac S by Zoetis, Strepguard by MSD Animal Health and 
Strepvax II by Boehringer Ingelheim) with unclear efficacy (Waller, 2014). New vaccines are 
under development. One example is a vaccine targeting 6-poly-N-acetyl glucosamine (PNAG) 
that appears to partly protect horses against Rhodococcus equi. A study on sera from strangles-
infected horses indicates that the vaccine also could be effective against S. equi (Cohen et al., 
2017). Strangvac (Intervet) is a subunit vaccine under development that is composed of 
recombinant polypeptides (CCE, Eq85, and IdeE). Clinical trials show that intramuscular 
injections may protect against and reduce clinical signs of S. equi (Flock et al., 2017). 
Researchers are also working on a vaccine based on a modified superantigen (SzeQ). This 
superantigen normally leads to a misdirection of the immune response (Waller et al., 2017).  
There is a lack of vaccines that makes it possible to differentiate between infected/previously 
infected and vaccinated animals (so called DIVA-vaccines). A DIVA-vaccine would be 
necessary for effective serological disease control and eventual eradication of disease is areas 
with vaccinated horses (Newton, Robinson & Waller, 2016). Newton et al. (2017) investigated 
Equilis streptE (MSD Animal Health) and found that the vaccine contributed to seropositivity 
in vaccinated horses when analysed with iELISA (Newton et al., 2017). El-Hage et al. (2017) 
suggest that there is a potential for DIVA in a cell free extract vaccine (Equivac, Zoetis), using 
iELISA. According to their study, the vaccine would not greatly interact with detection of cases 
of strangles but they assert that a larger study is needed for confirmation of this (El-Hage et al., 
2017).   
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Treatment 
Treatment recommendations for horses with strangles are today inconsistent. Many horses 
recover spontaneously but some need medical treatment. Surgical drainage and flushing of 
mature abscesses can fasten the course of the disease. Fluid therapy and intensive care can be 
necessary in severely affected horses and tracheotomy may be essential and lifesaving in horses 
with severe dyspnea (Reed, Bayly & Sellon, 1998).  
Anti-inflammatory treatment 
Anti-inflammatory medication, as NSAIDs, can be used as treatment of horses with strangles 
as it reduces the fever, lessens the pharyngeal discomfort and improves the demeanor. Horses 
with purpura haemorrhagica may need treatment with corticosteroids as dexamethasone (Yelle, 
1987; Reed, Bayly & Sellon, 1998).  
Chronic carriers 
To reduce the risk of spreading strangles treatment of chronic carriers can be necessary. 
Common treatment of these horses includes flushing of the guttural pouches with saline. Local 
and systemic treatment with antibiotic and local treatment with Acetylcysteine to resolve 
empyema and chondroids has been described. Destruction or removing of chondroids in the 
guttural pouches can in some cases be necessary. Removal of the chondroids is usually carried 
out with endoscopically guided instruments. Surgical removal, that before was common, seems 
only to be necessary in certain cases (Newton, Wood & Chanter, 1997; Verheyen et al., 2000). 
According to a study by Verheyen et al. (2000), a combination of these treatment methods 
showed varying results. Of 14 horses with varying clinical signs, 5 only required removal of 
inflammatory material from the guttural pouches and systemic treatment with sulphonamide 
for three weeks while 4 of 14 needed further removal of inflammatory content as well as topical 
and systemical treatment with sulphonamide. The remaining 5 horses also needed topical and 
systemic treatment with penicillin or ceftiofur before they were counted as free from chronic 
infection. Most horses required repeated rounds of flushing of the guttural pouches. The authors 
point out that future controlled studies of treatment of chronic carriers are needed (Verheyen et 
al., 2000).  
Antibiotics 
There is a debate regarding the use of antibiotics in horses with strangles. In review articles, 
books and antibiotic policies it is suggested that horses treated with antibiotics are unlikely to 
develop immunity to the bacteria and that treatment of subclinically infected horses and horses 
with abscesses only delay onset of clinical signs. It has also been argued that an impaired 
immunity could increase the risk of bacteremia, septicemia and metastatic abscessation. 
Unfortunately, there is currently not enough research that supports or refutes this (Reed, Bayly 
& Sellon, 1998; Harrington, Sutcliffe & Chanter, 2002; Sweeney et al., 2005; SVS, 2013; 
Waller, 2014; Duffee et al., 2015).  
There are studies supporting a positive effect of antibiotic treatment in horses with strangles. 
Evers (1968) observed that horses with experimental infection with S. equi treated with 
furaltadone hydrochloride (an antimicrobial metabolite of Nitrofuran) led to a decrease in body 
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temperature and nasal and ocular discharge. The horses also became more alert and their 
appetite increased. Horses treated only 24 hours after fever and nasal and ocular discharge first 
occurred did not develop abscesses. Piché (1984) reports that three stallions with anorexia, fever 
and depression, treated with intravenous Oxytetracyclin for one week and intramuscular 
benzylpenicillin procaine for one week or only benzylpenicillin procaine for ten days were free 
from clinical signs after a few to five days. Additionally, all the foals at the farm were treated 
with antibiotics prophylactically when their body temperature reached 38,5°C. The treatment 
was continued until at least one week after the foals were free from fever. All foals developed 
disease after completed treatment but they did not acquire any abscesses (Piché, 1984). 
Christmann and Pink (2015) concludes that an antibiotic regime during a large strangles 
outbreak coincided with reduced incidence and eventually the resolution of the outbreak. This 
was however only an observational study (Christmann & Pink, 2015). There are also studies 
indicating that antibiotic treatment improves blood values. Evers (1968) observed a decrease 
level of leucocytes after early treatment with Furaltadone and Neamat-Allah & El Damaty 
observed that hematological, biochemical and acid base parameters improved after treatment 
with procaine penicillin for 10 days (Neamat-Allah & El Damaty, 2016; Evers, 1968).  
One hypothesis is that antibiotic treatment prolongs the course of the disease (Sweeney et al., 
2005). Piché (1984) conclude that prophylactic treatment, in previously mentioned foals, may 
have delayed the disease development but also suggests that colostrum intake might have 
played a role. The treatment program was discontinued after weaning and then all foals 
contracted the disease (Piché, 1984). In the ACVIM Consensus Statement, by Sweeney et al. 
(2005), it is written that treatment of horses with immature abscesses is thought to prolong the 
course of disease as it is supposed to prolong enlargement and time to rupture of the abscesses. 
Surgical draining could therefore be indicated before antibiotic treatment. Something to 
consider is however that the abscesses may have a honeycomb structure and that surgical 
draining then only may lead to minimal exudate drainage. In severely affected horses with 
partial airway obstruction, antibiotics is probably indicated to reduce abscess size (Sweeney et 
al., 2005).  
Yelle (1987) recommend, in a review article, high doses of penicillin procaine for a prolonged 
period (1 to 6 months) to treat intraabdominal abscesses (Yelle, 1987). Prolonged intravenous 
antibiotic treatment was by Berlin et al. (2013) reported to cure four horses with suspected 
intraabdominal S. equi-abscesses. All horses were treated with high doses of Penicillin (44 000 
IU/kg) for over one month of time (Berlin et al., 2013). There is no evidence in the literature 
that antibiotic treatment increase the risk for metastatic abscessation (Duffee et al., 2015). 
Penicillin is the antibiotic of choice against S. equi. Streptococcal resistance against penicillin 
is not documented for any species, in Sweden or in other countries (Sweeney et al., 2005; SVS, 
2013; Waller, 2014; MPA, 2015). There is no documentation about S. equi and resistance in 
Sweden but for S. zooepidemicus no isolates were found resistant to penicillin and 6% were 
resistant to trimethoprim sulphamethoxazole in 2016 (Public Health Agency of Sweden and 
National Veterinary Institute, 2017). There are a few studies from other countries, covering the 
susceptibility of antibiotics to different streptococci. S. equi resistance to gentamicin (51,9%), 
trimethoprim sulfamethoxazole (25,9%), enrofloxacin (18,5%), doxycyclines (4,2%) and 
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tetracyclins (4,2%) was observed in one retrospective study with cases from the Royal 
Veterinary College Diagnostic Laboratory from 1999 to 2012. The bacteria were in the same 
study susceptible to both ceftiofur, penicillin and oxytetracyclin in all examined cases (Johns 
& Adams, 2014). Another similar study was done on cases from 2000 to 2010, at the University 
of Kentucky Veterinary Diagnostic Laboratory. S. equi was in this study 91,3% resistant to 
Sulfa drugs, 42% to trimethoprim and sulfamethoxazole, 13,2% to novobiocin, 10,5% to 
gentamycin and 0,9% to tetracycline. No resistance was reported to penicillin but 1,3% of the 
bacteria had only an intermediate susceptibility (Erol et al., 2012). 
Limited research is done on the susceptibility of different antibiotics to strangles in vivo in 
horses with or without abscesses. Ensink, Smit & Duijkeren (2003) showed that trimethoprim 
sulfamethoxazole did not eliminate bacteria in horses with S. zooepidemicus implanted 
subcutaneously in tissue chambers. In seven of eight horses, no bacteria were however 
demonstrated in tissue chambers after treatment with penicillin. The authors states that a 
probable reason to that trimethoprim sulfamethoxazole is less effective is an inhibited action of 
the antibiotic in purulent material but other factors may also have played a role (Ensink, Smit 
& Duijkeren, 2003). No similar study is done on S. equi. Christmann and Pink (2015) reports 
about an outbreak where ceftiofur seemed to have an effect against S. equi in vivo (Christmann 
& Pink, 2015).  
In Sweden, there is no specific recommended dose of benzylpenicillin procaine for treatment 
of strangles. Commonly used doses of benzylpenicillin procaine, independent on type of 
infection, are around 25 mg/kg (corresponds to 25 000 IU/Kg) every 12th or 24th hour (MPA, 
2015). MPA (2015) suggest that the dose of 20 mg/kg every once a day should be enough for 
the majority of streptococcal infections according to PK/PD-data (MPA, 2105). Timoney 
(2015) and Radostits (2007) recommended benzylpenicillin procaine doses of 22 000 IU/kg 
every 12th hour as treatment of horses with strangles (Radostits, 2007; Timoney, 2015). Ensink, 
Smit & Duijkeren (2003) considered the dose 20 000 IU/kg penicillin procaine once a day to 
be sufficient for treatment of horses with S. zooepidemicus implanted subcutaneously in tissue 
chambers and mean that the dose regime on 20 000 IU/kg twice daily is unnecessary. This was 
based on a study showing that 12 000 IU/kg was enough to reach MIC for both S. zooepidemicus 
and S. equi (Ensink et al., 1993). According to Ensink et al. (1993), MIC were the same for S. 
zooepidemicus and S. equi in an in vitro-examination. In the earlier mentioned outbreak, 
reported by Piché (1984), benzathine penicillin at a dose of 30 000 IU/kg was given to all foals 
twice a day while affected horses with ruptured abscesses were given benzylpenicillin procaine 
at the dose 25 000 IU/kg twice a day (Piché, 1984). In the outbreak reported by Christmann and 
Pink (2015), the penicillin procaine dose was 20 000 IU/kg twice a day. Regarding intravenous 
treatment, MPA (2015) recommend benzylpenicillin sodium at 10 mg/kg (corresponds to 
approximately 17 000 IU/kg) every 12th hour for treatment of streptococcal infections but they 
also state that there is no proof for effective treatment in cases with abscesses present (MPA, 
2015). Radostits (2007) recommends intravenous treatment with potassium or sodium 
benzylpenicillin at a dose of 22000 IU/kg every 6 hour (Radostits, 2007).  
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Antibiotics and relationship to development of antibodies 
Sweeney et al. (2005) referring to Piché (1984), states that antibiotic treatment in horses with 
early strangles may be curative but also will inhibit synthesis of protecting antibodies (Sweeney 
et al., 2005). Piché (1984) reports about the previously mentioned prophylactic treatment 
regime for foals. The foals were the only animals that during the outbreak that were treated in 
an early stage of disease (prophylactic treatment initiated when the body temperature reached 
38,5°C). All foals acquired strangles subsequent to completion of the treatment regime but they 
did not develop any abscesses. The outbreak of strangles was almost over when the treatment 
program ended and the reduced degree of environmental contamination and thereby challenge 
dose may have contributed to reduced severity of the infection. Piché (1984) also comments 
that it is possible that the foals, during treatment, were sufficiently antigenically stimulated to 
produce some circulating antibodies that later reduced the severity of clinical disease (Piché, 
1984). Eventual impaired development of immunity is hypothesized to be caused by altered 
protein synthesis of the bacteria because of antibiotic treatment or by acting of antibiotics on 
the bacterial cell wall, inhibiting cells from forming antibodies (Sweeney et al., 2005). Few 
reports, except the one by Piché (1984) include information about the rate of reinfection in 
antibiotic treated horses with strangles. Duffé et al. (2015) reports about recurring strangles in 
two cases (3%) of a total of 63 antibiotic treated strangles infected horses, treated with 
trimethoprim-sulfamethoxazole and oxytetracycline respectively. Unfortunately, time or 
duration for treatment was not recorded in the study (Duffé et al., 2015).  
Future challenges  
There are several questions about strangles that are not yet answered and a lot of statements 
without support in the literature. Several fields need more research. For example, there is no 
effective and secure vaccine which makes it possible to distinguish between vaccinated and 
infected horses (Waller, 2014), there is a lack of information about the survival of S. equi in the 
environment and there are still many unanswered questions regarding chronic carriers of 
strangles. In addition to this, there is no research about how antibiotic treatment affects 
immunity and disease duration. The aim with this project is to look closer into how treatment 
with antibiotics affect the immunity. 
MATERIALS AND METHODS 
Description of the outbreak 
Information and data from an outbreak of strangles on a Swedish Icelandic horse farm 2015 
was used in this project. The index-case was a horse returning to the farm after rehabilitation 
the 12th of April 2015. The 22nd of April it developed nasal discharge and fever. Samples were 
taken for suspected strangles and the diagnosis was confirmed the 24th of May. The following 
week more horses showed clinical signs of disease. Initially, affected horses were isolated but 
as the outbreak proceeded this measure was no longer possible. Most horses started to show 
clinical signs in the end of April/beginning of May. While severity of clinical signs varied 
between horses all but one horse had fever at some point. However, given that this was a natural 
field outbreak detailed information about clinical signs was not available for all horses. By the 
end of September, all horses were clinically healthy from strangles. At that time some horses 
were still positive on nasal lavage samples and/or guttural pouch samples and thus were treated 
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for carriage of S. equi. Subsequent sampling and endoscopies were done during late 2015 and 
2016 and by the last sampling occasion that took place the 22nd of August 2016, every horse 
had been tested negative on at least one occasion.  
At the beginning of the outbreak there were 43 adult horses at the farm. Two horses were 
euthanized in May 2015, before the sampling period started, because of development of clinical 
signs of strangles in combination with advanced age and poor dentition. One horse was 
euthanized in November 2015 because of laminitis and one in December 2015 because of 
peritonitis. One horse moved from the farm in December 2015 after it was tested free from S. 
equi. Two new horses arrived at the farm in 2016, they did not acquire clinical signs of strangles. 
No horse had been vaccinated against S. equi. 
Examinations and sampling 
During the outbreak, samplings and clinical examinations of the horses were done on several 
occasions by the district veterinarians of the area, and by veterinarians at Swedish university of 
agriculture (SLU) and UDS horse clinic (Figure 1). Rectal temperatures were documented by 
the horse owners for most horses daily during the early period of the outbreak (24th of April to 
20th of May). Horses with rectal temperatures over 38,2ºC were deemed as febrile.  
The first cases were diagnosed by samples taken by the district veterinarians. Following nasal 
lavage samples were taken by a veterinarian at SLU, over a period of 14 months, and analysed 
by culturing and qPCR. Samples for qPCR and culturing were also taken from the guttural 
pouches on 6 occasions. All horses were not sampled on every occasion. Horses positive on 
qPCR or culture, on either a nasal lavage sample or a guttural pouch sample, in the beginning 
of March 2016 were classified as chronic carriers of S. equi.  
Serological blood samples were collected on seven occasions over 10 months. The samples 
were analysed for the previously described antigen A and antigen C (iELISA from AHT). 
Horses with iELISA od values (optical density at 450 nm) for respective antigen over or equal 
to 0,5 were classified as seropositive.  
 
Figure 1. Time line from the beginning of the outbreak in April 2015 until March 2016. Green arrows 
represent serology sampling occasions and yellow arrows represents occasions for nasal lavage 
sampling and clinical examinations. Guttural pouch sampling occasions are not included in the time 
line. Examinations and sampling occasions carried out by the district veterinarians and UDS are not 
shown.  
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Treatment 
Twenty-two horses were treated with antibiotics at least once during the outbreak. According 
to the district veterinarians, only severely affected horses were treated with antibiotics during 
the initial period of the outbreak. Reasons for antibiotic treatment in the acute phase were 
mainly decreased appetite, high and/or persistent fever and decreased demeanor.  
The most commonly used antibiotic was Benzylpenicillin Procaine given intramuscularly. The 
Benzylpenicillin Procaine1 dose was around 20 mg/kg. Most horses were treated once a day but 
some horses got Benzylpenicillin Procaine twice a day. Some horses were referred to UDS 
horse clinic and were treated with Benzylpenicillin sodium2 intravenously. Two horses were 
treated with Sulfadiazine and Trimethoprim3. These were not treated during 2015. Duration of 
antibiotic treatment varied (table 1). 
Totally 14 of 38 horses (37%) were identified as chronic carriers; horses qPCR positive on 
either a nasal lavage sample or a guttural pouch sample in Mars 2016, about 11 months after 
the beginning of the outbreak (table 6). Five of these were also positive on culture. Treatment 
of these chronic carriers included flushing of the guttural pouches and systemic and/or topical 
antibiotic treatment. Some of these horses had also been treated during the acute phase of the 
outbreak. 
Sampled horses from the outbreak were put into three groups (table 1) based on time of 
antibiotic treatment in relation to appearance of clinical signs of strangles for two of the groups. 
The third group included those horses that developed strangles but were not administered any 
antibiotics during acute illness. Six horses (group 1) were treated with antibiotics between 3 
and 16 days after the first horse showed signs of fever (>38,2ºC) and nasal discharge. These 
horses were considered to have been treated early during the outbreak. No horse got earlier 
treatment. Horses in the second group were treated with antibiotics in 2015 but later than 16 
days after the first horse started to show clinical signs of disease. One horse in this group was 
treated with antibiotics because of a suspected intraabdominal S. equi abscess (table 2, horse 
nr. 11) and another (table 2, horse nr. 2) was treated because of a wound injury. Time from first 
clinical signs (body temperature > 38,2°C) for respective horse, to antibiotic treatment is shown 
in table 2.  
Table 1. Definition of group 1, 2 and 3 and the amount of horses (N) in each group 
Group 1 (N=6) Horses treated with antibiotics within 16 days after the first horse started 
showing clinical signs (rectal temperature > 38,2ºC). 
Group 2 (N=6) Horses treated with antibiotics between 16 days and 22 days after the first 
horse started showing clinical signs (rectal temperature > 38,2ºC). 
Group 3 (N=29) Horses not treated with antibiotics during the acute period.  
                                                          
1 Ethacilin vet., Wim de Körverstraat 35, P.O. Box 31, NL-5830 AN Boxmeer, the Netherlands  
2 Benzylpenicillin Panpharma, Z.I. du Clairy-Luitré, 35133, Fougères, France 
3 Hippotrim vet., Arne Jacobsens Allé 13, 2300 Köpenhamn S, Denmark 
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Duration of antibiotic treatment (table 2) in group 1 varied between 7 and 18-20 days (unsure 
information regarding treatment duration for horse 3). Three of these horses were partly treated 
with intravenous Benzylpenicillin sodium for 4 to 9 days. Horses in group 2 were treated 
between 5 and 54 days, 3 of them partly with Benzylpenicillin sodium intravenously. 
Table 2. Antibiotic treatment (Benzylpenicillin procaine and/or Benzylpenicillin sodium) for the horses 
in group 1 and 2 (treatment duration and x times a day) and time from first clinical signs (for the horse 
that first showed clinical signs and for the horse in question) to antibiotic treatment. Benzylpenicillin 
sodium were not used at the same time as benzylpenicillin sodium but before or after the period of 
benzylpenicillin sodium treatment. Eventual additional treatment during 2016 is not included  
Group  Horse 
nr. 
Benzylpenicillin procaine Benzylpenicillin 
sodium 
Time from that the 
first horse started 
showing clinical signs 
to antibiotic treatment 
Time from first 
clinical sign for the 
individual horse to 
antibiotic treatment 
Group 1 1 8 days x 1 - 7 days 3 days 
2 7 days x 1 - 12 days 10 days 
3 1 day x 1 + 8-10 days x 2 9 days x 3 15 days 8 days 
4 7-10 days x 1-2 5 days x 3 16 days 16 days 
5 1 day x 1 + 10 days x 2 4 days x 3 16 days 11 days 
6 7 days x 1 - 16 days 9 days 
Group 2 7 10 days x 1 - 22 days 7 days 
8 8 days x 1-2 5 days x 3 22 days 6 days 
9 14 days x 1 + 3 days x 2 15 days x 4  43 days 1-2 months 
10 10 days x 1  - 49 days 26 days 
11 4 days x 1 + 10 days x 1 40 days x 4 60 days 33 days 
12 5 days - 61 days 43 days 
 
Of 35 horses, 32 were on one or more occasions treated with Meloxicam4. Some horses were 
administered Flunixin meglumine5 intravenously during their stay at the UDS horse clinic. The 
dose for Meloxicam were 0,6 mg/kg and for Flunixin meglumine 1,1 mg/ml once a day. 
Treatment duration varied between horses. 
The horses in the three groups were between 7 and 32 years old and there was no significant 
difference in age between the groups. 
  
                                                          
4 Metacam for horses, 55216 Ingelheim/Rhein, Tyskland 
5 Flunixin N-vet, Uppsala Science Park, 751 83, Uppsala, Sweden 
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Statistical analysis 
Serological values, PCR results, rectal temperatures, antibiotic treatments and other information 
from veterinary journals (District veterinarians and UDS) and horse owners were compiled in 
an excel document.  
Descriptive statistics were recorded for the raw and graded (negative versus suspicious versus 
positive) serological response from the horses in group 1, 2 and 3 and groups response in 
relation to antibiotic treatment compared by the Fishers exact test. 
RESULTS 
All horses had qPCR positive nasal lavage samples on either the first (39/41 positive horses) or 
the second sampling occasion. Most of the horses (29/40) also had positive culture results 
during the first sampling occasion. All horses showed at some point positive results on qPCR 
to S. equi.  
All sampled horses had positive iELISA values for antigen A at some point. On the other hand 
3 of 41 horses did not have values over or equal to 0,5 for antigen C at any occasion. Antigen 
C values were negative in a higher frequency than Antigen A values. The following diagrams 
(diagram 1, 2 and 3) show the percentage of iELISA positive horses from the three groups. The 
diagrams are based on values shown in table 3, 4 and 5.  
On the first sampling occasion, about one month after the beginning of the outbreak 44% of the 
horses were positive for both antigen A and C (diagram 1, table 3). No significant difference 
between the groups was observed. About 3 weeks later the proportion of positive horses had 
increased but there was still no significant difference between the different groups. However, 
by the end of August the biggest difference between groups is observed with significant 
difference over time between group 1 and 2 where the percentage positive horses in group 2 
was 83% compared to 0% in group 1 (P= 0.015). In March 2017, a decrease in positive horses 
was seen also in group 2 but this was not statistically significant. 
 
Diagram 1. Percent horses positive for both antigen A and antigen C over time. 
15 
 
Table 3. a. Amount of horses positive for both antigen A and C on different occasions. b. P-values 
achieved when comparing the groups with Fisher’s exact test 
a. 
Group  2015-05-18 2015-06-09 2015-08-25 2016-03-02 
Group 1 3/6 (50%) 4/6 (66%) 0/6 (0%) 1/6 (17%) 
Group 2 2/6 (33%) 5/6 (83%) 5/6 (83%) 2/6 (33%) 
Group 3 13/29 (45%) 22/29 (76%) 11/28 (39%) 12/26 (46%) 
b. 
Groups compared  2015-05-18 2015-06-09 2015-08-25 2016-03-02 
1 and 3 1,0000 0,6353 0,1454 0,3606 
1 and 2 1,0000 1,0000 0,0152 1,0000 
2 and 3 0,6804 1,0000 0,0782 0,6722 
 
Most horses (90%) were on the first sampling occasion positive for antigen A (diagram 2, table 
4). Group 2 and group 3 are relatively stable over time while a decrease in positive horses are 
observed in group 1. A significant difference is seen between group 1 and 3 in the end of August 
(P=0,0305) and in March 2016 (P=0,0063). A significant difference is also observed between 
and group 1 and 2 (P=0,0152) in March 2016. 
 
Diagram 2. Percent horses positive for antigen A over time. 
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Table 4. a. Amount of horses positive for antigen A on different occasions. b. P-values achieved when 
comparing the groups with Fisher’s exact test 
a. 
Group  2015-05-18 2015-06-09 2015-08-25 2016-03-02 
Group 1 6/6 (100%) 5/6 (83%) 2/6 (33%) 1/6 (17%) 
Group 2 6/6 (100%) 6/6 (100%) 6/6 (100%) 5/6 (83%) 
Group 3 25/29 (86%) 29/29 (100%) 23/28 (82%) 21/26 (81%) 
b. 
Groups compared  2015-05-18 2015-06-09 2015-08-25 2016-03-02 
1 and 3 1,0000 0,1714 0,0305 0,0063 
1 and 2 1,0000 1,0000 0,0606 0,0152 
2 and 3 1,0000 1,0000 0,5585 1,0000 
 
For Antigen C (diagram 3, table 5), the percentage positive horses was in average 44% on the 
first sampling occasion. In August 2015, the amount of positive horses had decreased in group 
1 and 3. No significant decrease was observed between the groups at this time. In March 2016, 
the percentage positive horses was similar in all groups. 
 
 
Diagram 3. Percent horses positive for antigen C over time. 
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Table 5. a. Amount of horses positive for antigen C on different occasions. b. P-values achieved when 
comparing the groups with Fisher’s exact test 
a. 
Group  2015-05-18 2015-06-09 2015-08-25 2016-03-02 
Group 1 3/6 (50%) 5/6 (83%) 1/6 (17%) 3/6 (50%) 
Group 2 2/6 (33%) 5/6 (83%) 5/6 (83%) 3/6 (50%) 
Group 3 13/29 (45%) 22/29 (76%) 11/28 (39%) 12/26 (46%) 
b. 
Groups compared  2015-05-18 2015-06-09 2015-08-25 2016-03-02 
1 and 3 1.0000 1.0000 0.3891 1.0000 
1 and 2 1.0000 1.0000 0.0801 1.0000 
2 and 3 0.6804 1.0000 0,0782 1.0000 
 
DISCUSSION 
Among many veterinarians, it is commonly presumed that treatment with antibiotics in horses 
with strangles may lead to a lack of antibodies and a risk of reinfection. However, in searching 
the literature, there is little information to support this concept. The aim with this study was to 
look closer into the subject and examine whether antibiotics in horses affects the serological 
antibody response.  
All horses in this study were at some point positive on nasal lavage samples analysed by qPCR 
and were in other words exposed for antigenic stimuli. During the first sampling occasion 39 
of 41 horses (95%) were positive on qPCR while only 29 of 40 (72,5%) were positive on culture. 
This strengthens the fact that qPCR is a more sensitive method for diagnosing strangles in 
horses than culture (Båverud, Johansson & Aspan, 2007; Webb et al., 2012; Lindahl et al., 
2013). Horses in this project were continuously positive on PCR even if the number of positive 
horses decreased. For example on the 21th of May 95% of the horses were PCR positive and 
the 25th of August 26% were still PCR positive. Additionally, there was a recrudescence of PCR 
positivity in November 2015 (not shown in the results). As the horses were not isolated from 
each other, it was assumed that horses comingling may have been antigenically stimulated and 
thus affecting the antibody response in a manner of vaccine booster effect. As this often is the 
case in natural outbreaks, the results are of interest but difficult to explain in this work.  
Two antigens were examined when using the AHT’s iELISA serology test. The test is mainly 
constructed as a diagnostic device. Looking at the percentage of horses that were positive for 
both antigens there was mainly a difference in august 2015 between 1 and 2 (P=0.0152). 
Positive serology samples for both antigen may indicate a good immune response. Even if there 
was a difference between A significant difference between group 1 and 2 indicate a difference 
between earlier and later treated horses but it is notable that a significant difference was not 
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observed at the first two sampling occasions, closest after time of treatment. Additionally, there 
is no difference between group 1 and 3.  
Antigen C consists of a part the SeM protein. This protein is an important antiphagocytic 
virulence factor of S. equi and a loss of the SeM expression lead to loss of full virulence of the 
bacteria (Hoffman, 1991; Hamlen, Timoney & Bell, 1994; Harrington, Sutcliffe & Chanter, 
2002; Timoney, 2004). Hamlen, Timoney and Bell (1994) showed that protection against 
strangles in foals were associated with high ELISA values of SeM IgG while it in other studies 
have been observed that resistance against S. equi in infected or vaccinated horses was 
independent of bactericidal levels of SeM antibodies in serum (Galan & Timoney, 1984; 
Timoney & Eggers. 1985). Although sensitivity and specificity combining antigen A and C, 
was 93,3% respective 99,3% in a study (Robinson et al., 2013), the sensitivity and specificity 
for only antigen C (a part of SeM) was 59,6% respective 100% with an 0,5 od value as 
breakpoint. In a recent study by Tscheschlok et al. (2017), only 7 of 112 horses in a natural 
outbreak of strangle, had been seropositive for antigen C on at least one sampling occasions, 
19 weeks after the outbreak resolution (opposed to antigen A, where 91 of 112 horses had been 
seropositive on at least one occasion). The morbidity was in that outbreak was only 53% and 
only 34 of 112 horses had clinical strangles. The authors discuss that a reason for this may be a 
less pathogen strain of S. equi, possibly because of an observed deletion of the gene SEQ_0402. 
There were however no changes in the SeM-gene. It is also possible that the low morbidity was 
due to a low infectious dose (Tscheschlok et al., 2017). Mentioned studies indicate that it is not 
obvious that high levels of antibodies against SeM/antigen C in sera is correlated to protection 
against S. equi.  Thus the lack of robust seroconversion and retention of antibodies to Antigen 
C in this study raise questions regarding the sensitivity and specificity of the ELISA used  that   
relies of the Antigen C as a complement for the testing (Robinson et al. 2013).  
In this study, the proportion horses positive for antigen C was lower than the proportion positive 
for antigen A but only 3 of 40 horses had negative serology samples for the antigen over the 
whole sampling period. A non-significant difference between the groups were for antigen C 
observed in September 2015. As there were no significant differences and hesitant correlations 
between for seropositivity for antigen C and protection against strangles, these results do not 
support the hypothesis that antibiotics affect the development of antibodies in horses with early 
strangles.  
Information about the antigen C (recombinant N-terminal protein fragments of the EQ2190 
sequence) in the literature is lacking. EQ2190 is a sequence encoding for a putative sortage-
processed protein and it was identified in all examined strains in a study by Webb et al. (2015). 
Equal to antigen C, antigen A is an antigen unique for S. equi. Sensitivity for only antigen A 
was according to Robinson at al. (2013), 74,2% and specificity 99,3%, using an od value of 0,5 
as breakpoint. This higher sensitivity is in line with the outbreak described by Tscheschlok et 
al. (2017), where 91 of 112 horses were seropositive for antigen A. The higher prevalence of 
seropositivity compared to antigen C may possibly make antigen A a better measure of the 
antibody response but more information is needed to say whether there is any correlation 
between protection against S. equi and seropositivity for antigen A. 
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All horses had positive serology samples for antigen A during the first or second sampling 
occasion. At the first sampling occasion, most of the horses were positive. Antibodies against 
antigen A seem thereby to be more prevalent than antibodies against antigen C. Over time, the 
percentage positive horses for Antigen A decreased more in group 1 than in group 2 and 3. This 
is the only result that at some point may support the statement that treatment with antibiotics 
affect the development of protecting antibodies (Reed, Bayly & Sellon, 1998; Harrington, 
Sutcliffe & Chanter, 2002; Sweeney et al., 2005; SVS, 2013; Waller, 2014). Significant 
differences were however only observed in March 2016 (P=0,0152), when comparing group 1 
and 2 and in August 2015 (P=0,0305) and March 2016 (P=0,0063) when comparing group 1 
and 3. No significant differences were observed between the groups during the first two 
sampling occasions, closest to the time of treatment.  
There is research indicating that local immunity in the nasal mucosa is important for full 
protection against S. equi (Galan & Timoney, 1985; Sheoran, 1997). Sheoran et al. (1997) 
observed a strong local mucosal antibody response against SeM in infected horses but not in 
horses vaccinated with an intramuscularly administered SeM vaccine (Sheoran et al., 1997). 
Serum and mucosal antibodies seems to react to different parts of SeM and not all parts of the 
SeM seems to stimulate lymphocytes (Timoney et al., 2010). This suggests that different 
antigens stimulate the immune responses in different ways. During infection, all parts of S. equi 
are present and it is probable that all parts of the immune response are stimulated. The iELISA 
only gives a measure of the levels of antibodies against two antigens and does not give any 
information about local immunity or the cell mediated immune response. What also is 
discussible is which levels of antibodies that should be considered as protective and what should 
be considered as seropositivity.  
The hypothesis about an impaired development of immunity is directed to horses treated with 
antibiotics in an early stage of disease (Reed, Bayly & Sellon, 1998; Harrington, Sutcliffe & 
Chanter, 2002; Sweeney et al., 2005; SVS, 2013; Waller, 2014). The hypothesis is based on a 
study by Piché (1984) where foals on a farm were treated with antibiotics prophylactically when 
they reached a body temperature of 38,5ºC. Opposed to foals in the study by Piché (1984), the 
horses in this study were not treated until they showed severe clinical signs. According to AHT 
(n.d.), it takes approximately 2 weeks after infection before enough antibodies for protection 
can be found in sera. With an incubation time of 3 to14 days (Sweeney et al., 2005), the 
antibiotic treated horses were probably exposed to antigen before they started to show clinical 
signs. It is therefore probable that the antibiotic treated horses in the present study already had 
developed some amount of antibodies before the treatment started. As the horses in group 1 
were the earliest treated horses, they were however considered to be least likely to have 
developed a higher level of antibodies and how these horses were treated is more compatible 
with the reality and a restrictive usage of antibiotics than if they would have been treated at an 
earlier stage of disease.  
In the current study, horses were divided into groups based on at which time after the first horse 
started to show clinical signs, they were treated with antibiotics. It is possible that another group 
constellation would have given other results, especially as the early treated horses during this 
outbreak were few. With only 6 horses in group 1 and 2 it is hard to draw any real conclusions.  
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None of the horses at the farm showed clinical signs of reinfection and this may indicate that 
all horses had enough immunological response for protection against circulating antigen. This 
low frequency of reinfection is similar to what is reported in the study by Duffee et al. (2015) 
where only two of 63 horses had recurring strangles. That the frequency was higher in the 
outbreak reported by Piché (1984) may be due to earlier treatment or due to differences in the 
study populations as all horses referred to in the study by Piché (1984) were foals. It is however 
not known what would have happened if the horses in the present study would have been 
exposed to a clinically infected horse, possibly with a higher excretion of antigen.   
It should be taken in consideration that biological factors, as differences in immune response 
between horses, may have affected the results. According to the district veterinarians, only 
severely affected horses were treated with antibiotics. This implies that horses in group 1 and 2 
had a higher clinical scoring than horses in group 3. One hypothesis is that the horses in group 
1 had a lower immune defense from the beginning which may have affected the serological 
values. It is hard to confirm a difference in clinical scoring between the groups as there is not 
enough clinical information about all horses. Exact information about disease duration and 
clinical signs for each horse would have greatly assisted interpretation and grouping of 
treatments.  
Duration and type of penicillin varied somewhat between the horses in group 1 and 2. Given 
the high sensitivity of S. equi to penicillin an influence on eventual decreased development of 
antibodies is not probable. However, it is possible that treatment duration and penicillin dose 
has an impact on the effectiveness when treating for example horses with abscesses.  
Treatment with anti-inflammatory medicines was common during the outbreak. When 
analysing the immunity there were no consideration taken to treatment with anti-inflammatory 
medicines. This does not exclude the possibility that anti-inflammatory treatment may affect 
immunity to S. equi. There is however no evidence that this would be the case.  
The sampling occasions from November 2015 were not included in the results. During these 
sampling occasions, there were a rise in horses positive on qPCR (nasal lavage samples) and 
seropositive horses. Antibiotic treated horses were not PCR-positive in a higher degree than 
non-antibiotic treated horses. The reason for what caused the immunostimulation in November 
2015 is not known. This is emphasizing the difficulty of doing research on real cases and 
outbreaks. It is probable that what happened in November 2015 has affected the serology results 
in March 2016.   
It is possible that treatment with antibiotics can prolong the course of disease in horses with 
abscesses. Long-term treatment has in some cases been proved to cure horses with 
intraabdominal abscesses (Berlin et al., 2013). If treatment is discontinued before the abscess 
is totally healed it is possible that it will start growing again until it ruptures. During this 
outbreak, one gelding with an ultrasonically diagnosed abscess in the abdomen of about 7 cm, 
were treated for 54 days with Penicillin (table 2, horse number 11). The abscess decreased in 
size during the treatment period and was no longer visible when the treatment was discontinued. 
Unfortunately, long term treatment with Penicillin is hard to acquire outside a hospital, making 
this treatment quite expensive.  
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After this study, it is not possible to say whether the hypothesis that early antibiotic treatment 
in horses in strangles affect the development of antibodies is true or not. There is lot of factors 
that are unsure, making it impossible to draw any conclusions. Whether antibiotics affect the 
immune response or not, it is always important to be restrictive with antibiotics. Streptococcal 
resistance against Penicillin is not reported but it is possible that the situation will be different 
in the future (Sweeney et al., 2005; SVS, 2013; Waller, 2014; MPA, 2015). Resistance to other 
antibiotics against S. equi has been observed. Treatment with Penicillin is in many cases a 
challenge as it must be administered either intramuscularly or intravenously and there is also a 
risk for shocking with severe consequences. For these reasons, veterinarians may be tempted to 
choose other antibiotics that may have a higher risk for development of resistance and that may 
be less effective. Avoiding antibiotic treatment is advantageous as a part of a generally 
restrictive use of antibiotics. In spite of this, penicillin treatment should be considered to 
severely affected horses, to horses with prolonged clinical signs and in some cases when bastard 
strangles is suspected. To decrease spreading of disease, treatment could also be adequate in 
horses diagnosed as chronic carriers. For more evidence based recommendations, more research 
is however needed.  
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